To the Editor,Direct FXa inhibitor apixaban affects routine coagulation assays of PT/INR and APTT to some extent. Generally, increasing apixaban concentrations only modestly prolongs coagulation times . Yet, responses are reagent-dependent and laboratories need to recognize the sensitivities of their reagents. Previously, we conducted a survey in 73 and 22 European laboratories with dabigatran and rivaroxaban, respectively, to assess the anticoagulant effects on routine coagulation assays .Here, we repeated the survey using apixaban. In September 2015, an EQA organization Labquality Ltd (Finland) sent lyophilized apixaban samples (kindly donated by Pfizer Finland) to 28 European laboratories participating in an anti-Xa EQA round (Finland, Denmark, Estonia, Greece, Iceland, Ireland, Norway) spiked in different concentrations: 80 ng/mL (Diagnostica Stago), 120 ng/mL (Technoclone), 270 ng/mL (Stago), and 300 ng/mL (Technoclone). Laboratories were instructed to reconstitute the samples with distilled water and incubate for 30 min at room temperature, before analysis. They were instructed to report INR, APTT and anti-Xa (with both heparin and apixaban calibration), where available.Twenty-one laboratories reported results (16 Finland, one Estonia, one Greece, one Iceland, one Ireland, one Norway). The laboratories included 10 university centers (five in Finland), with other participants being regional laboratories. PT results were reported as activity
Clinical Chemistry and Laboratory Medicine (CCLM) – de Gruyter
Published: Jul 26, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera